Session » Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster I

Date: Sunday, November 5, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 321

A Meta-Analysis of 4 Clinical Trials of Denosumab Compared with Bisphosphonates in Postmenopausal Women Previously Treated with Oral Bisphosphonates

9:00AM-11:00AM: Abstract Number: 318

A Randomized Alendronate-Controlled Trial of Romosozumab: Results of the Phase 3 Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk

9:00AM-11:00AM: Abstract Number: 327

Association of Anti-Cyclic Citrullinated Peptide Seropositivity and Lean Mass Index with Low Bone Mineral Density in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 333

Atypical Femoral Fracture in Patients of a Rheumatology Service: Clinical, Radiographic and Bone Histomorphometric Data

9:00AM-11:00AM: Abstract Number: 331

Case Series: Comparison of Repository Corticotropin Injection (H.P. Acthar Gel) Versus Glucocorticoids on Bone Density in SLE Patients

9:00AM-11:00AM: Abstract Number: 330

Change in Bone Mineral Density in Patients with Rheumatoid Arthritis: Minimal 10-Year Follow-up

9:00AM-11:00AM: Abstract Number: 323

Evaluation of Invasive Oral Procedures and Events in Women with Postmenopausal Osteoporosis Treated for up to 10 Years with Denosumab: Results from a Phase 3 Open-Label Extension Study

9:00AM-11:00AM: Abstract Number: 329

Factors Associated with Worsening Serum Vitamin D Deficiencies in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study

9:00AM-11:00AM: Abstract Number: 326

Osteoporosis and Vertebral Fractures Are Associated with Disease Activity, Low Vitamin D Levels and Spinal Radiographic Damage in Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 322

Safety of Denosumab in a Monocentric Cohort of Kidney Transplant Recipients

9:00AM-11:00AM: Abstract Number: 328

Secular Trends in the Risk of Fragility Fracture Among Patients with Rheumatoid Arthritis: A General Population-Based Study

9:00AM-11:00AM: Abstract Number: 332

Serum 25-Hydroxyvitamin D, Acute Phase Reactants and Disease Activity in Rheumatologic Diseases

9:00AM-11:00AM: Abstract Number: 320

Teriparatide Compared with Risedronate and the Risk of Clinical Vertebral Fractures: 2-Year Results of a Randomized, Double-Dummy Clinical Trial

9:00AM-11:00AM: Abstract Number: 319

The Placebo-Controlled Fracture Study in Postmenopausal Women with Osteoporosis: The Foundation Effect of Rebuilding Bone with One Year of Romosozumab Leads to Continued Lower Fracture Risk after Transition to Denosumab

9:00AM-11:00AM: Abstract Number: 324

The Predictors of the Efficacy of Denosumab, a Monoclonal Antibody to RANK Ligand, on Osteoporosis in Rheumatoid Arthritis Patients from Japanese Multicenter Study

9:00AM-11:00AM: Abstract Number: 325

Zoledronic Acid Did Not Impaired Renal Function in Patients with Osteoporosis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].